Latest Articles and Analysis

Nevada expands syringe vending machines with naloxone, fentanyl strips; anonymity critical for uptake.

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.

Monitoring report documents HCV treatment access challenges across ADAP, Medicaid, and VA systems.

Overdose Awareness Day calls for holistic interventions addressing SUD as a health issue, not criminal one.

Stigma drives opposition to harm reduction programs like safe consumption sites despite strong evidence.

Q3 2022 review of HCV drug access across ADAPs, Medicaid, and comprehensive harm reduction programs.

Community-based low-barrier HCV treatment for PWID significantly improves liver health outcomes.

Conference examines HIV and methamphetamine use intersection among MSM and transgender communities.

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

DOJ clarifies ADA protections for people with opioid use disorder against discrimination.

Medicaid sobriety restrictions on HCV treatment contradict harm reduction and elimination goals.

Biden's SOTU addresses harm reduction, endorses MAT Act; limited HIV-specific programming focus.

NIH issues RFAs for Harm Reduction Network; Biden agenda targets decriminalization and safe consumption.

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

COVID-19 strains public health efforts addressing HIV outbreaks, diverting resources from the domestic epidemic.

Study explores social-spatial networks and HIV/HCV diagnosis rates among homeless and injection drug users.

WHO 2030 HCV elimination goal at risk; only 5 of 110 countries on track as COVID-19 disrupts progress.

Q3 2021 quarterly review of HCV drug access across ADAPs and Medicaid with harm reduction program updates.

CANN roundtable discusses pandemic's impacts on HIV, HCV, STI, and SUD programs and funding weaknesses.